Protein trafficking defects in inherited kidney diseases

Nephrology Dialysis Transplantation

Volumn 29, Issue , 2014, Pages iv33-iv44

  Schaeffer, Céline ^a   Creatore, Anna ^a   Rampoldi, Luca ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Inherited kidney disease; Misfolded protein; Molecular and pharmacological chaperone; Protein homeostasis; Protein trafficking

Indexed keywords

AMILORIDE; DESMOPRESSIN; PYRIDOXINE; SAPROPTERIN; TAFAMIDIS; THIAZIDE DIURETIC AGENT; MISFOLDED PROTEIN; PROTEIN;

AGXT GENE; AQP2 GENE; AVPR2 GENE; CLCN5 GENE; DENT DISEASE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EPITHELIUM CELL; FAMILIAL AMYLOIDOSIS; FLUID THERAPY; GENE; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPEROXALURIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY TUBULE ACIDOSIS; LIDDLE SYNDROME; MOLECULAR GENETICS; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; OCRL1 GENE; PATHOGENESIS; PHENYLKETONURIA; PRIMARY HYPEROXALURIA TYPE I; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN TRANSPORT; PSEUDOHYPOALDOSTERONISM; PSEUDOHYPOALDOSTERONISM TYPE 2; REVIEW; SCNN1B GENE; SCNN1G GENE; SODIUM RESTRICTION; ANIMAL; GENETIC PREDISPOSITION; GENETICS; INHERITED KIDNEY DISEASE; METABOLISM; MOLECULAR AND PHARMACOLOGICAL CHAPERONE; PATHOLOGY; PROTEIN HOMEOSTASIS; PROTEIN TRAFFICKING;

INHERITED KIDNEY DISEASE; MISFOLDED PROTEIN; MOLECULAR AND PHARMACOLOGICAL CHAPERONE; PROTEIN HOMEOSTASIS; PROTEIN TRAFFICKING;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY DISEASES; PROTEIN TRANSPORT; PROTEINS;

EID: 84910134320     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu231     Document Type: Review

References (98)

1. Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375: 1287-1295
2. Parenti G, Pignata C, Vajro P et al. New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med 2013; 31: 11-20
3. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 2013; 34: 278-301
4. Kamsteeg EJ, Hendriks G, Boone M et al. Short-chain ubiquitination mediates the regulated endocytosis of the aquaporin-2 water channel. Proc Natl Acad Sci USA 2006; 103: 18344-18349
5. Rosenthal W, Seibold A, Antaramian A et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 1992; 359: 233-235
6. Pan Y, Metzenberg A, Das S et al. Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat Genet 1992. 2: 103-106
7. Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 2012. 27: 2183-2204
8. Barak LS, Oakley RH, Laporte SA et al. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 2001; 98: 93-98
9. Hermosilla R, Oueslati M, Donalies U et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 2004; 5: 993-1005
10. Postina R, Ufer E, Pfeiffer R et al. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus. Mol Cell Endocrinol 2000; 164(1-2): 31-39
11. Robben JH, Sze M, Knoers NV et al. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Mol Biol Cell 2006; 17: 379-386
12. Los EL, Deen PM, Robben JH. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus. J Neuroendocrinol 2010; 22: 393-399
13. Bernier V, Morello JP, Zarruk A et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17: 232-243
14. Robben JH, Kortenoeven ML, Sze M et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA 2009; 106: 12195-12200
15. Revankar CM, Cimino DF, Sklar LA et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630
16. Dupre DJ, Baragli A, Rebois RV et al. Signalling complexes associated with adenylyl cyclase II are assembled during their biosynthesis. Cell Signal 2007; 19: 481-489
17. Olesen ET, Rutzler MR, Moeller HB et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 2011; 108: 12949-12954
18. Li JH, Chou CL, Li B et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest 2009; 119: 3115-3126
19. Van Lieburg AF, Verdijk MA, Knoers VV et al. Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene. Am J Hum Genet 1994; 55: 648-652
20. Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006; 291: F257-F270
21. De Mattia F, Savelkoul PJ, Kamsteeg EJ et al. Lack of arginine vasopressininduced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J Am Soc Nephrol 2005; 16: 2872-2880
22. Savelkoul PJ, De Mattia F, Li Y et al. p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced phosphorylation. Hum Mutat 2009; 30: E891-E903
23. Kamsteeg EJ, Wormhoudt TA, Rijss JP et al. An impaired routing of wildtype aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J 1999; 18: 2394-2400
24. De Mattia F, Savelkoul PJ, Bichet DG et al. A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type aquaporin-2 rescues the apical membrane expression of intracellularly retained AQP2-P262L. Hum Mol Genet 2004; 13: 3045-3056
25. Sohara E, Rai T, Yang SS et al. Pathogenesis and treatment of autosomaldominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. Proc Natl Acad Sci USA 2006; 103: 14217-14222
26. Yang B, Zhao D, Verkman AS. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J 2009; 23: 503-512
27. Hart TC, Gorry MC, Hart PS et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39: 882-892
28. Rampoldi L, Scolari F, Amoroso A et al. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 2011; 80: 338-347
29. Bernascone I, Janas S, Ikehata M et al. A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating defect and renal failure. Hum Mol Genet 2010; 19: 2998-3010
30. Kemter E, Prueckl P, Sklenak S et al. Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice. Hum Mol Genet 2013; 22: 4148-4163
31. Raffi H, Bates JM, Laszik Z et al. Tamm-Horsfall protein knockout mice do not develop medullary cystic kidney disease. Kidney Int 2006; 69: 1914-1915
32. Drozdova T, Papillon J, Cybulsky AV. Nephrin missense mutations: induction of endoplasmic reticulum stress and cell surface rescue by reduction in chaperone interactions. Physiol Rep 2013; 1: e00086
33. Pieri M, Stefanou C, Zaravinos A et al. Evidence for activation of the unfolded protein response in collagen IV nephropathies. J Am Soc Nephrol 2014; 25: 260-275
34. Chen YM, Zhou Y, Go G et al. Laminin beta2 gene missense mutation produces endoplasmic reticulum stress in podocytes. J Am Soc Nephrol 2013; 24: 1223-1233
35. Purdue PE, Takada Y, Danpure CJ. Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol 1990; 111 (6 Pt 1): 2341-2351
36. Williams EL, Acquaviva C, Amoroso A et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 2009; 30: 910-917
37. Leiper JM, Oatey PB, Danpure CJ. Inhibition of alanine:glyoxylate aminotransferase 1 dimerization is a prerequisite for its peroxisome-tomitochondrion mistargeting in primary hyperoxaluria type 1. J Cell Biol 1996; 135: 939-951
38. Fargue S, Lewin J, Rumsby G et al. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem 2013; 288: 2475-2484
39. Mesa-Torres N, Fabelo-Rosa I, Riverol D et al. The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I. PLoS ONE 2013; 8: e71963
40. Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed Res Int 2013; 2013: 687658
41. Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 2003; 18: 986-991
42. Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 2013; 1832: 1776-1783
43. Alper SL. Familial renal tubular acidosis. J Nephrol 2010; 23(Suppl 16): S57-S76
44. Karet FE, Finberg KE, Nelson RD et al. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 1999; 21: 84-90
45. Sly WS, Whyte MP, Sundaram V et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med 1985; 313: 139-145
46. Bruce LJ, Cope DL, Jones GK et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 1997; 100: 1693-1707
47. Tanphaichitr VS, Sumboonnanonda A, Ideguchi H et al. Novel AE1 mutations in recessive distal renal tubular acidosis. Loss-of-function is rescued by glycophorin A. J Clin Invest 1998; 102: 2173-2179
48. Kollert-Jons A, Wagner S, Hubner S et al. Anion exchanger 1 in human kidney and oncocytoma differs from erythroid AE1 in its NH2 terminus. Am J Physiol 1993; 265(6 Pt 2): F813-F821
49. Cordat E, Kittanakom S, Yenchitsomanus PT et al. Dominant and recessive distal renal tubular acidosis mutations of kidney anion exchanger 1 induce distinct trafficking defects in MDCK cells. Traffic 2006; 7: 117-128
50. Walsh S, Turner CM, Toye A et al. Immunohistochemical comparison of a case of inherited distal renal tubular acidosis (with a unique AE1 mutation) with an acquired case secondary to autoimmune disease. Nephrol Dial Transplant 2007; 22: 807-812
51. Jarolim P, Shayakul C, Prabakaran D et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3 - exchanger. J Biol Chem 1998; 273: 6380-6388
52. Devonald MA, Smith AN, Poon JP et al. Non-polarized targeting of AE1 causes autosomal dominant distal renal tubular acidosis. Nat Genet 2003; 33: 125-127
53. Fry AC, Su Y, Yiu V et al. Mutation conferring apical-targeting motif on AE1 exchanger causes autosomal dominant distal RTA. J Am Soc Nephrol 2012; 23: 1238-1249
54. Toye AM, Williamson RC, Khanfar M et al. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. Blood 2008; 111: 5380-5389
55. Bruce LJ, Pan RJ, Cope DL et al. Altered structure and anion transport properties of band 3 (AE1, SLC4A1) in human red cells lacking glycophorin A. J Biol Chem 2004; 279: 2414-2420
56. Patterson ST, Reithmeier RA. Cell surface rescue of kidney anion exchanger 1 mutants by disruption of chaperone interactions. J Biol Chem 2010; 285: 33423-33434
57. Chu CY, King JC, Berrini M et al. Functional rescue of a kidney anion exchanger 1 trafficking mutant in renal epithelial cells. PLoS ONE 2013; 8: e57062
58. Lloyd SE, Pearce SH, Fisher SE et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379: 445-449
59. Hoopes RR, Jr, Shrimpton AE, Knohl SJ et al. Dent disease with mutations in OCRL1. Am J Hum Genet 2005; 76: 260-267
60. Devuyst O, Christie PT, Courtoy PJ et al. Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease. Hum Mol Genet 1999; 8: 247-257
61. Devuyst O, Thakker RV. Dent's disease. Orphanet J Rare Dis 2010; 5: 28
62. Piwon N, Gunther W, Schwake M et al. ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease.Nature 2000; 408: 369-373
63. Wang SS, Devuyst O, Courtoy PJ et al. Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum Mol Genet 2000; 9: 2937-2945
64. Gunther W, Luchow A, Cluzeaud F et al. ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci USA 1998. 95: 8075-8080
65. Novarino G, Weinert S, Rickheit G et al. Endosomal chloride-proton exchange rather than chloride conductance is crucial for renal endocytosis. Science 2010; 328: 1398-1401
66. Christensen EI, Devuyst O, Dom G et al. Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 2003; 100: 8472-8477
67. Claverie-Martin F, Ramos-Trujillo E, Garcia-Nieto V. Dent's disease: clinical features and molecular basis. Pediatr Nephrol 2011; 26: 693-704
68. Lin Z, Jin S, Duan X et al. Chloride channel (Clc)-5 is necessary for exocytic trafficking of Na+/H+ exchanger 3 (NHE3). J Biol Chem 2011; 286: 22833-22845
69. Moulin P, Igarashi T, Van Der Smissen P et al. Altered polarity and expression of H+-ATPase without ultrastructural changes in kidneys of Dent's disease patients. Kidney Int 2003; 63: 1285-1295
70. Lippiat JD, Smith AJ. The CLC-5 2Cl(-)/H(+) exchange transporter in endosomal function and Dent's disease. Front Physiol 2012; 3: 449
71. Lourdel S, Grand T, Burgos J et al. ClC-5 mutations associated with Dent's disease: a major role of the dimer interface. Pflugers Arch 2012; 463: 247-256
72. Wu F, Roche P, Christie PT et al. Modeling study of human renal chloride channel (hCLC-5) mutations suggests a structural-functional relationship. Kidney Int 2003; 63: 1426-1432
73. Grand T, Mordasini D, L'hoste S et al. Novel CLCN5 mutations in patients with Dent's disease result in altered ion currents or impaired exchanger processing. Kidney Int 2009; 76: 999-1005
74. D'antonio C, Molinski S, Ahmadi S et al. Conformational defects underlie proteasomal degradation of Dent's disease-causing mutants of ClC-5. Biochem J 2013; 452: 391-400
75. Quilty JA, Li J, Reithmeier RA. Impaired trafficking of distal renal tubular acidosis mutants of the human kidney anion exchanger kAE1. Am J Physiol Renal Physiol 2002; 282: F810-F820
76. Terryn S, Jouret F, Vandenabeele F et al. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes. Am J Physiol Renal Physiol 2007; 293: F476-F485
77. Gorvin CM, Wilmer MJ, Piret SE et al. Receptor-mediated endocytosis and endosomal acidification is impaired in proximal tubule epithelial cells of Dent disease patients. Proc Natl Acad Sci USA 2013; 110: 7014-7019
78. Pirruccello M, De Camilli P. Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL. Trends Biochem Sci 2012; 37: 134-143
79. Hichri H, Rendu J, Monnier N et al. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat 2011; 32: 379-388
80. Shrimpton AE, Hoopes RR, Jr, Knohl SJ et al. OCRL1 mutations in Dent 2 patients suggest a mechanism for phenotypic variability. Nephron Physiol 2009; 112: p27-p36
81. Shimkets RA,Warnock DG, Bositis CM et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79: 407-414
82. Hansson JH, Nelson-Williams C, Suzuki H et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995; 11: 76-82
83. Snyder PM, Price MP, Mcdonald FJ et al. Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell 1995; 83: 969-978
84. Warnock DG. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int 1998; 53: 18-24
85. Staub O, Dho S, Henry P et al. WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J 1996; 15: 2371-2380
86. Jones ES, Owen EP, Davidson JS et al. The R563Q mutation of the epithelial sodium channel beta-subunit is associated with hypertension. Cardiovasc J Afr 2011; 22: 241-244
87. Hiltunen TP, Hannila-Handelberg T, Petajaniemi N et al. Liddle's syndrome associated with a point mutation in the extracellular domain of the epithelial sodium channel gamma subunit. J Hypertens 2002; 20: 2383-2390
88. Rotin D, Schild L. ENaC and its regulatory proteins as drug targets for blood pressure control. Curr Drug Targets 2008; 9: 709-716
89. Ronzaud C, Staub O. Ubiquitylation and control of renal Na+ balance and blood pressure. Physiology (Bethesda) 2014; 29: 16-26
90. Wilson FH, Disse-Nicodeme S, Choate KA et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293: 1107-1112
91. Louis-Dit-Picard H, Barc J, Trujillano D et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 2012; 44: 456-460, S1-3
92. Boyden LM, Choi M, Choate KA et al. Mutations in Kelch-like 3 and Cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012; 482: 98-102
93. Ronzaud C, Loffing-Cueni D, Hausel P et al. Renal tubular NEDD4-2 deficiency causes NCC-mediated salt-dependent hypertension. J Clin Invest 2013; 123: 657-665
94. Fischer H, Fukuda N, Barbry P et al. Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 2001; 281: L52-L57
95. Naik S, Zhang N, Gao P et al. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases. Curr Top Med Chem 2012; 12: 2504-2522
96. Muntau AC, Leandro J, Staudigl M et al. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis 2014; doi: 10.1007/s10545-014-9701-z [epub ahead of print]
97. Lindquist SL, Kelly JW. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol 2011; 3: a004507
98. Mu TW, Ong DS, Wang YJ et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008; 134: 769-781